Spinal Cord Injury - Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD

Drug

Standing/walking/mobility

Online since 6 November 2021, updated 1182 days ago

About this trial

This is a trial to test the effect of a drug (NeuroAiD) in patients with spinal cord injury. NeuroAiD is a “natural product” in several formulations given in oral capsule form that contain Chinese herbal and other ingredients. If included, the participant will receive NeuroAiD for 6 months in addition to standard care and will be monitored for 24 months. The treatment duration is 6 months and participants will be monitored for 24 months (follow-up assessments occur at 1, 3, 6, 12, 18, and 24 months). All participants are allowed to receive standard care and other therapies and treatments

Included participants

Gender

All

Age

18 - 65 years

Injury level

C1 - S5

Severity (AIS)?

AIS-A

AIS-B

Time since injury

3 days - 4 weeks

Injury type

Traumatic

Healthy volunteers

C1-S5

What’s involved

Type

Drug

Details

The total duration of the study is 24 months and will involve the following: If included, the participant will take NeuroAiD oral capsules as directed for 6 months in addition to undergoing standard care treatments Follow-up assessments will occur at 1, 3, 6, 12, 18, and 24 months and will consist of neurological exams to assess changes in muscle and sensory function and questionnaires. Side effects will also be followed.

Potential benefits

Main benefits

Standing/walking/mobility

Additional benefits

Arm/hand function

General health

Mental health and psychosocial factors

Sensory function

Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

Wings for Life supports SCITrialsFinder

Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

Learn more

Back to results